Active Biotech AB (ACTI.ST)

ACTI.ST on Stockholm Stock Exchange

25.90SEK
26 Mar 2015
Change (% chg)

-0.70kr (-2.63%)
Prev Close
26.60kr
Open
26.50kr
Day's High
26.60kr
Day's Low
25.60kr
Volume
99,845
Avg. Vol
244,193
52-wk High
35.87kr
52-wk Low
15.50kr

ACTI.ST

Chart for ACTI.ST

About

Active Biotech AB is a Sweden-based company that focuses on pharmaceutical research and development in medical fields in which the immune system plays a central role. The Company’s research portfolio primarily includes projects for the development of drugs for the treatment of autoimmune and inflammatory diseases and cancer. As... (more)

Overall

Beta: 2.04
Market Cap(Mil.): kr2,391.56
Shares Outstanding(Mil.): 89.91
Dividend: --
Yield (%): --

Financials

  ACTI.ST Industry Sector
P/E (TTM): -- 133.09 40.89
EPS (TTM): -2.93 -- --
ROI: -36.82 -0.49 15.96
ROE: -57.11 -2.27 16.81
Search Stocks

BRIEF-Active Biotech posts big Q4 operating loss

* Q4 operating result -55.6 million SEK (-80.4] Source text for Eikon: Further company coverage:

11 Feb 2015

REFILE-BRIEF-Active Biotech says SEK 225 mln rights issue oversubscribed

* Active Biotech: Active Biotech's rights issue of approximately SEK 225 million oversubscribed Source text for Eikon: Further company coverage: (Reporting By Simon Johnson)

30 Dec 2014

BRIEF-Active Biotech says 225 mln SEK rights issue oversubscribed

* Active biotech : active biotech's rights issue of approximately sek 225 million oversubscribed Source text for Eikon: Further company coverage: (Reporting By Simon Johnson)

29 Dec 2014

BRIEF-Active Biotech Q3 operating loss SEK 56 mln

STOCKHOLM, Nov 5 - Active Biotech Ab, July-September:

05 Nov 2014

BRIEF-Active Biotech and Teva expand Laquinimod clinical development program

* Teva and Active Biotech announce expansion of Laquinimod clinical development program with new trial in primary progressive multiple sclerosis and first patient screened in Huntington's Disease trial Source text for Eikon: Further company coverage:

04 Nov 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Sadif Analytics Prime
$10.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks